Online first
Original paper
Published online: 2024-03-13
Cystatin C improves cardiovascular risk prediction in cardiometabolic patients in addition to estimated glomerular filtration rate
Abstract
Not available
Keywords: Cystatin Ccardiovascular diseaseglomerular filtration rate
References
- Ferguson TW, Komenda P, Tangri N. Cystatin C as a biomarker for estimating glomerular filtration rate. Curr Opin Nephrol Hypertens. 2015; 24(3): 295–300.
- Krstic D, Tomic N, Radosavljevic B, et al. Biochemical Markers of Renal Function. Curr Med Chem. 2016; 23(19): 2018–2040.
- Levey AS, Fan Li, Eckfeldt JH, et al. Cystatin C for glomerular filtration rate estimation: coming of age. Clin Chem. 2014; 60(7): 916–919.
- Onopiuk A, Tokarzewicz A, Gorodkiewicz E. Cystatin C: a kidney function biomarker. Adv Clin Chem. 2015; 68: 57–69.
- Carvalho LS, Silva TQ, Coelho-Filho OR. Cystatin C as a Candidate Biomarker of Cardiovascular Outcomes: Too Near, but too Far from Reality. Arq Bras Cardiol. 2018; 111(6): 808–809.
- Magnusson M, Molvin J, Engström G, et al. Cystatin C and Risk of Diabetes and the Metabolic Syndrome - Biomarker and Genotype Association Analyses. PLoS One. 2016; 11(5): e0155735.
- van der Laan SW, Fall T, Soumaré A, et al. Cystatin C and Cardiovascular Disease: A Mendelian Randomization Study. J Am Coll Cardiol. 2016; 68(9): 934–945.
- Luo J, Wang LP, Hu HF, et al. Cystatin C and cardiovascular or all-cause mortality risk in the general population: A meta-analysis. Clin Chim Acta. 2015; 450: 39–45.
- Xu Y, Ding Y, Li X, et al. Cystatin C is a disease-associated protein subject to multiple regulation. Immunol Cell Biol. 2015; 93(5): 442–451.
- Satoh-Asahara N, Suganami T, Majima T, et al. Japan Obesity and Metabolic Syndrome Study (JOMS) Group. Urinary cystatin C as a potential risk marker for cardiovascular disease and chronic kidney disease in patients with obesity and metabolic syndrome. Clin J Am Soc Nephrol. 2011; 6(2): 265–273.
- Dejenie TA, Abebe EC, Mengstie MA, et al. Dyslipidemia and serum cystatin C levels as biomarker of diabetic nephropathy in patients with type 2 diabetes mellitus. Front Endocrinol (Lausanne). 2023; 14: 1124367.
- Dedual MA, Wueest S, Challa TD, et al. Obesity-Induced Increase in Cystatin C Alleviates Tissue Inflammation. Diabetes. 2020; 69(9): 1927–1935.